Sustained Efficacy and Safety of Tildrakizumab in Psoriasis Vulgaris Despite Multiple Prolonged Treatment Interruptions: A Case Report

Psoriasis vulgaris is a persistent inflammatory skin disease that often necessitates long-term biologic therapy to maintain symptom control and prevent flares. Interruptions in biologic treatment are sometimes unavoidable due to individual health concerns or external circumstances, but the impact of repeated, extended gaps in therapy remains insufficiently understood. We describe a case involving a woman with moderate-to-severe psoriasis vulgaris who achieved sustained remission using tildrakizumab, even after multiple treatment interruptions, each lasting over a year. The patient initially received various conventional and biologic treatments before transitioning to tildrakizumab. Despite prolonged discontinuations prompted by personal concerns, she consistently regained complete skin clearance within months of restarting therapy. No therapy-related adverse events were recorded during any biologic treatment period. This case emphasizes the potential resilience of tildrakizumab efficacy in the setting of intermittent administration, suggesting its suitability for patients who may face unavoidable gaps in care. Further research is warranted to evaluate immunogenicity risks and long-term effectiveness in larger, diverse patient populations.